Serum insulinlike growth factor is not elevated in XXXX with @entity1582 but is still a prognostic factor.

@entity1582 @entity1 @entity442 @entity2301
@entity442 ( @entity442 ) has growth-promoting effects on @entity1582 cells in vitro as well as in vivo. In this study, we measured the concentration of @entity442 and its major binding protein, @entity2301 ( @entity2301 ), in serum from 127 @entity1 with @entity1582 . Serum had been drawn at the time of diagnosis, before treatment with high-dose melphalan. @entity2301 in @entity1582 @entity1 (1.6 +/- 0.73 microg/mL; mean +/- SD) was significantly decreased compared to healthy age- and sex-matched controls (2.2 +/- 0.42 microg/mL). However, @entity2301 had no prognostic value in this study. The mean @entity442 level did not differ between @entity1582 @entity1 (17.8 +/- 7.7 nM) and controls (17.3 +/- 5.6 nM). Nevertheless, @entity442 was a strong indicator of prognosis. After 80 months of follow-up, @entity1582 @entity1 with low levels (< 13 nM) of serum @entity442 had not reached median survival. In the @entity1 group with @entity442 levels above 13 nM, median survival was 62 months (P =.006). These findings support the hypothesis of a role for @entity442 in @entity1582 progression.
